Evidence map›Paper›PMID 30922345›Full record

ArticleDiagnostic pathology2019

Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass.

Haiyan Bao, Juehua Gao, Yi-Hua Chen, Jessica K Altman, Olga Frankfurt, Amanda L Wilson, Madina Sukhanova, Qing Chen, Xinyan Lu

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Haiyan BaoDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, ward 3-140, Chicago, IL, 60611, USA.
Juehua GaoDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, ward 3-140, Chicago, IL, 60611, USA.
Yi-Hua ChenDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, ward 3-140, Chicago, IL, 60611, USA.
Jessica K AltmanDepartment of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Olga FrankfurtDepartment of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Amanda L WilsonDepartment of Pathology, Aurora Medical Center, Pathology, Kenosha, WI, USA.
Madina SukhanovaDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, ward 3-140, Chicago, IL, 60611, USA.
Qing ChenDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, ward 3-140, Chicago, IL, 60611, USA.
Xinyan LuDepartment of Pathology, Northwestern University Feinberg School of Medicine, 303 East Chicago Avenue, ward 3-140, Chicago, IL, 60611, USA. Xinyan.lu@northwestern.edu.
Northwestern University · USAurora Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroudMyeloid sarcoma (MS) is a rare neoplasm of immature myeloid precursors that form tumor mass outside the bone marrow. The diagnosis of de novo MS can be challenging, particularly in patients with no prior history of hematologic malignancies or when MS involves unusual anatomic sites. CASE PRESENTATION: The patient was a 53-year-old woman with a history of uterine fibroids and vaginal bleeding for many years who presented with a vaginal wall mass. The tumor had histologic and phenotypic features of histiocytic sarcoma, however, overlapping with a possible extramedullary MS. Using a comprehensive genomic profiling, we were able to identify recurrent chromosomal aberrations associated with MS including a rare KMT2A-ELL fusion, losses of chromosomes 1p, 9, 10, 15, 18, and gain of chromosome 1q and mutations in FLT3 and PTPN11, and achived the final diagnosis of a de novo MS. The patient received standard treatment for acute myeloid leukemia regimen with stem cell transplantation and achieved complete remission.

conclusionOur case illustrates the clinical utility of comprehensive genomic profiling in assisting the diagnosis or differential diagnosis of challenging MS or histiocytic sarcoma cases, and in providing important information in tumor biology for appropriate clinical management.

Indexed as

Chromosome AberrationsFemaleGene FusionHistone-Lysine N-MethyltransferaseHumansLeukemia, Myeloid, AcuteMiddle AgedMyeloid-Lymphoid Leukemia ProteinSarcoma, MyeloidStem Cell TransplantationTranscriptional Elongation FactorsTreatment OutcomeVaginaELL protein, humanHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinTranscriptional Elongation FactorsCopy number aberrationsCytogeneticsHistiocytic sarcomaKMT2A-ELL fusionMolecularMyeloid sarcomaOncoScanSNP microarray

Identifiers

PMID30922345
PMCPMC6440110
OpenAlexW2933536823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.